Portable CO2 Fractional Laser Machine 10600nm Cosmetic Skin Resurfacing

Emmalaser Co., Limited 

 is one of the leading manufacture of professional advanced beauty equipments and medical devices.
Our products are widely selling in cosmetics, aesthetics and dermatology fields. We supply Intensive Pulse Light (IPL) Laser machine, C02 Laser machine. 808nm Diode Laser machine, Q-Switched ND:YAG Laser machine, Cyrolipolysis machine.PDT LED Therapy machine, Ultrasonic Cavitation, EMSlim,hifu machine, etc.

Today company employs 300+ staffand 90% of employees have undergraduate educational background.We have already installed thousand spieces of equipments and our products cover more than 100 countries.Our engineers have obtained 40+ patents & trademarks in laser technology,RF technology, cooling systems.

We work to create a market with science & technology to make humanbeings benefit from that in wellness and beauty filed. By combining sci-ence and technology with medical market perfectly

What is CO2 fractional laser?
The CO2 Fractional resurfacing laser is carbon dioxide laser which precisely removes deep outer layers of damaged skin and stimulates the regeneration of healthy skin underneath. The CO2 treats fine to moderately deep wrinkles, photo damage, scarring, skin tone, texture, crepiness and laxity.

What are the benefits of CO2 fractional laser?
The New Standard: Benefits of Fractional CO2 Laser Skin Resurfacing
Minimizes sun damage, acne scars, and fine lines.
Improves skin texture and evens skin tone.
Stimulates collagen for firmer, more youthful skin.
May help treat pre-cancerous skin lesions.
Minimal downtime.

What is the principle of CO2 laser?
A CO2 laser is a gas laser with that A mixture of carbon dioxide, nitrogen and helium serves as an active medium. The carbon dioxide molecules are stimulated. If an infrared photo meets a carbon dioxide molecule, a new photon is created

What is the success rate of CO2 laser treatment?
Full-face laser resurfacing was performed in 81.1% of patients, with 64.3% receiving their treatment under local anesthesia without sedation. Length of hyperemia was less than five weeks in 93%, five to eight weeks in 5.9%, and more than eight weeks in 0.9% of patients.